|Bid||10.65 x 168100|
|Ask||10.85 x 50000|
|Day's Range||8.98 - 9.21|
|52 Week Range||7.65 - 13.68|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Nicox SA, which obtained U.S. regulatory approval for two products this year, is “no longer at risk of disintegrating,” according to Chief Executive Officer Michele Garufi.
Valeant subsidiary Bausch + Lomb, along with Nicox S.A., received FDA application approval for a new glaucoma drug.